Corporate News & Publications

CLINUVEL's company releases, including archives.

Tuesday, 13 December 2016 02:25

Appendix 3Y

Monday, 28 November 2016 15:01

Results of Meeting

Sunday, 27 November 2016 13:19

Managing Director's AGM Presentation

Melbourne, Australia and New York, US, 9 November 2016 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that it met on 7 November with the US Food and Drug Administration’s (FDA’s) Division of Dermatology and Dental Products (DDDP) to discuss the content and format of a new drug application (NDA) submission as part of the US regulatory pathway for CLINUVEL’s medicinal product SCENESSE® (afamelanotide 16mg). The pharmaceutical product has been developed for the treatment of erythropoietic protoporphyria (EPP)1, a rare genetic enzymatic disorder causing lifelong absolute light intolerance. The pre-NDA meeting allowed both parties to discuss…
Monday, 31 October 2016 14:16

Appendix 4C

Thursday, 27 October 2016 05:36

Appendix 4G

Monday, 24 October 2016 03:46

CLINUVEL relocates Melbourne office

Melbourne, Australia, October 24, 2016 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY) today announced that its head office in Melbourne has relocated. The new address, which will also be the Company’s Registered Address, is: Level 6 15 Queen Street Melbourne Victoria, Australia, 3000 All telephone and fax numbers remain the same. - End - For more information contact: CLINUVEL PHARMACEUTICALS LTD T: +61 3 9660 4900 E: This email address is being protected from spambots. You need JavaScript enabled to view it. This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and…

Quick Links